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ABSTRACT:
Purpose: Patients with advanced cholangiocarcinoma (CC) and gallbladder 
carcinoma (GC) have few therapeutic options for relapsed disease.  
Methods: Given the overall poor prognosis in this population and the availability 
of novel targeted therapies, we systematically analyzed the characteristics and 
outcomes for GC and CC patients treated on phase I trials with an emphasis on 
targeted agents and locoregional therapies. 
Results: Of 40 treated patients (GC=6; CC=34; median age, 60 years), 8 (20%) 
had stable disease (SD) > 6 months, 3 (8%) partial response (PR), on protocols with 
hepatic arterial drug infusion and anti-angiogenic, anti-HER-2/neu or novel MAPK/
ERK kinase (MEK) inhibitors.  Median progression-free survival (PFS) on phase I trials 
was 2.0 months (95% CI 1.7, 2.8) versus 3.0 months (95% CI 2.4, 5.0), 3.0 months 
(95% CI 2.3, 4.6), and 3.0 months (95% CI 2.4, 3.9) for their first-, second-, and 
last-line FDA-approved therapy. In univariate analysis, >3 metastatic sites, elevated 
alanine aminotransferase (ALT) (>56IU/L), serum creatinine (>1.6mg/dL), and 
CA19-9 (>35U/mL) were associated with a shorter PFS.  Mutational analysis revealed 
mutation in the KRAS oncogene in 2 of 11 patients (18%). The SD >6 months/PR 
rate of 28% was seen with hepatic arterial infusion of oxaliplatin, and inhibitors of 
angiogenesis, HER-2/neu or MEK. 
Conclusions: The PFS in phase I trials was similar to that of the first, second, 
and last-line therapy (P=0.95, 0.98, 0.76, respectively) with FDA-approved agents 
given in the advanced setting, emphasizing a role for targeted agents in a clinical 
trials setting as potentially valuable therapeutic options for these patients.  
INTRODUCTION
Cholangiocarcinoma (CC) and gallbladder 
carcinoma (GC) are rare, but aggressive, biliary tract 
malignancies characterized by their advanced stage at 
diagnosis and high mortality.  Though anatomically 
neighbors, GC and CC are histologically distinct entities 
arising from the epithelium of the gallbladder and hepatic 
bile ducts, respectively.[1] CC is further stratified by 
anatomic location, either intrahepatic or extrahepatic. 
CC and GC are challenging diseases to diagnose given 
their insidious evolution and lack of effective screening 
modalities.  With few cases (<10%) presenting as early 
disease, most patients are initially diagnosed with 
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metastatic disease that is not amenable to surgery.[2] 
Despite advancements in the multimodal approach to 
the treatment of advanced solid tumors, the prognosis of 
advanced CC and GC remains grim.[2-4] Unfortunately, 
epidemiological trends point towards an increasing 
incidence and prevalence of CC and GC in East Asia, 
Latin America and in western societies, particularly given 
their association with hepatitis C infection, chronic non-
alcoholic fatty liver disease and obesity.[5, 6]  Current 
Food and Drug Administration (FDA) approved agents 
used in unresectable CC and GC include gemcitabine, 
capecitabine, cisplatin, oxaliplatin, fluoropyrimidines, 
including 5-fluorouracil, or a combination of these agents, 
although none are FDA approved primarily for use in 
biliary tract cancers. [7, 8]  Recent protocols combine 
chemotherapy with radiation either in the preoperative 
neoadjuvant setting or in the postoperative setting.  Even 
multi-agent chemotherapeutic approaches do not confer a 
durable benefit in patients with metastatic and/or relapsed 
disease, and fewer than 5% of patients survive 5 years 
after advanced diagnosis.[9] 
We embarked on this study to analyze the 
characteristics and outcomes of patients with advanced CC 
and GC with very aggressive biology referred for phase I 
clinical trials at a major cancer center with an emphasis on 
targeted agents to elicit early response signals. 
PATIENTS AND METHODS
We reviewed the characteristics and outcomes of 
72 consecutive patients with GC and CC referred to the 
Clinical Center for Targeted Therapy (Phase I Clinical 
Trials Program) at MD Anderson Cancer Center starting 
from November 2004.  Eligibility criteria for participation 
in phase I clinical trials included age >18 years, presence 
of metastatic or unresectable disease, measurable disease 
per Response Evaluation Criteria in Solid Tumors 
(RECIST) 1.0,[10] Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) of 0-1,[11] and a life 
expectancy >3 months. Premenopausal women were 
required to have a negative pregnancy test and patients 
of childbearing potential to use contraception. Further 
eligibility criteria varied according to the particular study 
and all patients gave informed consent. This study and 
all clinical trials were approved by the MD Anderson 
Institutional Review Board.
After review of baseline clinical, laboratory, 
radiologic and pathologic data during the initial 
consultation, patients were enrolled on a phase I trial 
based on scientific rationale and protocol availability. 
After initiation of an investigational therapy, patients were 
evaluated at 2- to 4- week intervals, based on the specific 
protocol, with a medical history, physical examination, 
comprehensive series of laboratory tests, and assessments 
of toxicity and compliance.  Restaging scans were done 
every 6-8 weeks, depending on the protocol. Obstructive 
cholestasis were managed according to the patients 
performance status and clinical status by interventional 
radiologist intervention or a stent placement by the gastro-
intestinal consult team. 
Table 1: Patient Characteristics.
N %
Sex
Male 17 42.5%
Female 23 57.5%
Age at time of diagnosis, 
Median (range) 60.2 (21.6 - 73.6)
Age >60 21 52.5%
Age <60 19 47.5%
Race 
White 31 77.5%
African American 5 12.5%
Hispanic 4 10.0%
ECOG Performance Status
0-1 36 90.0%
2-3 4 10.0%
Tumor histology
Cholangiocarcinoma 34 85.0%
Intrahepatic 30
Extrahepatic 4
Gallbladder 
carcinoma 6 15.0%
Number of metastatic sites
Median (range) 3 0 - 6
0-2 10 25.0%
> 3 30 75.0%
Metastatic sites 
Liver 36 90.0%
Lymph nodes 33 82.5%
Peritoneum 15 40.0%
Lung 15 37.5%
Retroperitoneum 15 37.5%
Bone 6 15.0%
Pancreas 5 12.8%
Spleen 4 10.0%
Kidney 1 2.5%
Ovary 1 2.5%
Adrenal 1 2.5%
Prior treatments
Prior surgical 
resection 15 37.5%
Prior 
chemoembolization 3 7.5%
Prior radiation 13 32.5%
Number of prior systemic therapies
Median (range) 3 (0-11)
0-5 31 77.5%
>5 9 22.5%
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Endpoints and Statistical Methods
All statistical analysis was performed by our 
biostatistician (K.R.H.). Descriptive statistics summarized 
the patients’ characteristics. Cox proportional hazards 
regression analysis was used to examine the association 
between progression-free survival (PFS) since beginning 
phase I therapy and the following variables measured at 
the time of initial phase I consultation: age at diagnosis, 
gender, ECOG PS, number of metastatic sites, number 
of prior therapies, hemoglobin, lactate dehydrogenase 
(LDH), platelet count, history of thromboembolism, 
total bilirubin, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline phosphatase, 
serum sodium, serum creatinine, tumor markers 
(carcinoembryonic antigen [CEA], carbohydrate antigens 
[CAs] CA 19-9, CA 125, CA 27.29), presence of ascites, 
serum albumin, and the Royal Marsden Hospital (RMH) 
prognostic score (comprised of serum albumin <3.5 g/dL, 
lactate dehydrogenase > upper limit of normal and > 2 
metastatic sites).[12]  
Best response was assessed using RECIST 1.0 every 
2 cycles (6-8 weeks) of therapy as per the protocol.[10] 
Partial response (PR) was defined as a >30% decrease in 
the sum of the longest diameter of target lesions, excluding 
complete disappearance of disease (complete response, 
CR) and progressive disease (PD) was a > 20% increase. 
Stable disease (SD) was defined as changes that did not 
meet the criteria for a PR or PD. Waterfall plot analysis 
according to RECIST is used to illustrate response. 
Overall survival was measured from the date of 
enrollment on a phase I trial until death from any cause 
or date of last follow-up. PFS is defined as the time from 
first day of treatment on a phase I trial to date when 
treatment on the last phase I trial ceased due to disease 
progression or death, but not toxicity.  Patients still alive 
(in case of survival analysis) and free of progression (in 
case of PFS analysis) were censored at time of last follow-
up.  Toxicities were assessed using the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events, version per the protocol.[13]  A P-value <.05 was 
considered statistically significant.  Statistical analysis was 
performed using S-PLUS® 8.0 for Windows (Insightful 
Corp.).
Figure 1: Waterfall plot of the best RECIST response to the best phase I trial of all 40 treated patients. Six patients 
who did not undergo restaging due to early disease progression are reflected as a 20% increase. Time (in months) reflects the duration of 
response. 
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RESULTS
Patients Characteristics
Of the 72 patients with GC and CC referred to the 
Phase I Clinical Trials program, 32 patients (30 CC and 
2 GC) were not enrolled in a phase I clinical trial due to 
deterioration of performance status (N=25), decision to 
pursue alternate therapies including treatments closer to 
home (N=6), and insurance denial (N=1). Forty patients 
who participated in a phase I trial are included in this 
analysis. Pretreatment characteristics at presentation to 
the Phase I Clinic are summarized in Table 1. The median 
age at diagnosis was 60 years (range, 41.4-73.6 years). 
There were 23 women and 17 men.  Thirty-one (78%) 
were White, 5 (12%) were African American, and 4 (10%) 
were Hispanic.  Seven patients (18%) had an ECOG 
PS of 0, 29 patients (72%) had a PS of 1 and 4 (10%) 
patients a 2. Of the 40 patients treated, 6 had gallbladder 
carcinoma, 4 had extrahepatic cholangiocarcinoma and 30 
had intrahepatic cholangiocarcinoma; the tumor histology 
for all 40 patients was consistent with adenocarcinoma. 
The median number of metastatic sites was 3 (range 0-6). 
The most common sites of metastases at time of phase I 
referral were liver (90% of patients), lymph nodes (83%), 
peritoneum (40%), retroperitoneum (38%) and lung 
(38%).  The median time from initial phase I consultation 
to day one on a phase I trial was 16 days. 
Therapy before patient inclusion in phase I trials
Overall, of the 40 patients enrolled on a phase I 
trial, two patients had received no prior therapy because 
of the unavailability of reasonable, conventional therapy 
for the extent of their disease.  The remaining 38 patients 
had a median of 3 prior systemic therapies before referral 
to the Phase I Clinic (range, 1 – 11). Fifteen patients 
(38%) also underwent a prior surgical resection, whereas 
13 (33%) received prior radiation and 3 (8%) had prior 
chemoembolization.  
The National Comprehensive Cancer Network 
(NCCN) guidelines for unresectable gallbladder and 
cholangiocarcinoma include a gemcitabine/cisplatin 
combination therapy, fluoropyrimidine-based or other-
gemcitabine based regimen.[4, 14]  For their first-line 
treatment in the advanced/metastatic setting, 4 of 38 
patients received experimental therapy on phase II trials 
with a novel paclitaxel conjugate or a campotothecin 
analog. The remaining 34 patients received a first-
line regimen based on gemcitabine (N=24, 71%), a 
fluoropyrimidine (N=7, 21%), or single-agent sorafenib 
(N=3, 8%).  As their second-line therapy in the advanced 
disease setting, 36 patients received a regimen including 
gemcitabine (N=17, 47%), a fluropyrimidine (N=16, 45%), 
or a targeted agent (N=3, 8%); 2 patients did not received 
a second line treatment and instead began phase I therapy. 
All 38 patients were treated on a regimen based on FDA-
approved drugs as their last antineoplastic therapy before 
beginning a phase I trial; 58% received a fluoropyrimidine-
based regimen (26% received fluoropyrimidine agents 
in combination with platinum), whereas 23% received a 
Figure 2: Prolonged partial response for 12.1 months noted in the primary hepatic lesion of a patient with advanced 
cholangiocarcinoma treated with hepatic arterial infusion of a cytotoxic agent along with intravenous anti-angiogenic 
agent. CT scan of the abdomen showed liver metastases at baseline and after 12 months of treatment. White arrows show multiple areas 
of hypoattenuation secondary to splenic embolization.
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Table 2: Univariate Proportional Hazards Regression Model for 
Phase I Progression Free Survival (PFS)
N Median PFS (mos) Hazard ratio P-value
Gender 0.5 (0.3, 2.1)
Male : Female 17 : 23 2.9 : 2.5 0.75
Age (yrs) 0.7 (0.3, 1.8) 0.5
< 60 : >60 19 : 21 2.5 : 2.1
ECOG PS 2.2 (0.6, 7.5) 0.26
PS 0-1 : 2 36 : 4 2.5 : 1.4
Number of metastatic site 3.2 (0.7, 1.4) 0.07
1-2 : > 3 10 : 30 NR : 2.0
Number of prior therapies 0.9 (0.3, 2.5) 0.82
< 5  : > 5 31 : 9 2.1 : 2.9
Hemoglobin (g/dL) 1.7 (0.7, 4.0) 0.26
< 10.5 : > 10.5 25 : 15 NR : 2.0
LDH (IU/L) 1.0 (0.4, 2.5) 0.99
< 618 : > 618 27 : 13 2.5 : 2.0
Platelet count (K/UL) n/a n/a
< 439 : > 439 39 : 1 2.5 : NR
History of thromboembolism 1.1 (0.4, 3.0) 0.86
Yes : No 11 : 29 2.5 : 2.0
Total bilirubin (mg/dL) 1.6 (0.6, 4.2) 0.33
< 1: > 1 30 : 10 2.9 : 2.0
ALT (IU/L) 5.3 (1.8, 16) 0.0072
< 56 : > 56 35 : 5 NR : 1.3
AST (IU/L) 1.0 (0.4, 2.3) 0.91
< 46 : > 46 21 : 19 2.1 : 2.9
Alkaline phosphatase (IU/L) 0.6 (0.2, 1.5) 0.3
< 126 : > 126 12 : 28 2.0 : 2.9
Serum sodium (mEq/L) 1.4 (0.4, 4.6) 0.64
> 135 : < 135 36 : 4 2.1 : 2.4
Serum creatinine (mg/dL) n/a 0.022
< 1.6 : > 1.6 36 : 4 2 : NR
CEA (ng/mL) 1.2 (0.4, 3.8) 0.69
< 6 : > 6 33 : 7 2.5 : 1.8
CA-19-9 (U/ml) 4.8 (1.1, 21) 0.01
< 35 : > 35 11 : 29 NR : 2.0
CA 125 (U/ml) 1.1 (0.4, 2.6) 0.87
< 35 : > 35 20 : 20 2.0 : 2.9
CA 27.29 (U/ml) 1.2 (0.5, 3.0) 0.66
< 47 : > 47 22 : 16 2.5 : 2.0
Presence of ascites 1.1 (0.5, 2.7) 0.79
Yes : No 19 : 21 2.1 : 2.9
Serum albumin (g/dL) 1.5 (0.6, 3.8) 0.44
< 3.5 : > 3.5 29 : 11 2.5 : 2.0
RMH score 1.5 (0.6, 3.7) 0.34
0-1 : 2-3 21 : 19 2.9 : 2.0   
Abbreviations: ALT alanine aminotransferase; AST aspartate aminotransferase; 
ECOG, Eastern Cooperative Oncology Group; LDH lactate dehydrogenase; 
CEA Carcinoembryonic antigen; CA carbohydrate antigen; NR not reached; 
PS, performance status; RMH Royal Marsden Hospital; n/a Not applicable
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targeted agent, most commonly an angiogenesis inhibitor. 
Thus FDA-approved agents formed the backbone of the 
systemic combination therapy prior to enrollment in a 
phase I trial. 
Treatment
Overall, patients were initially treated on 1 of 22 
phase I clinical trials; of these trials, 8 patients received 
therapy on six first-in-human trials with novel targeted 
inhibitors against MEK, VEGF, gamma-secretase, 
aurora kinase and the IGF-IR pathway.  Of 40 patients, 
30 (75%) were treated on a trial with combination 
therapy of two or more agents while 10 patients (25%) 
received treatment with a single agent. Seventeen (43%) 
patients received locoregional treatment with direct 
infusion of a cytotoxic agent into the hepatic artery; 24 
(60%) received intravenous angiogenesis inhibitors, 
of whom 13 (33%) received the antiangiogenic agent 
in combination with hepatic arterial infusion therapy. 
Fifteen (38%) patients received targeted agent(s) alone, 
20 (50%) received targeted agent(s) in combination with 
cytotoxic chemotherapy, and 5 (12%) received cytotoxic 
chemotherapy alone. The median number of cycles 
received was 2 (range 1 – 12).  Six patients went on to 
receive therapy under a second phase I trial; of these 
patients, 3 received treatment on 3 phase I trials.
Response
Six patients were not restaged prior to end of 
cycle 2 due to clinical deterioration and early disease 
progression. Of the 40 patients treated on clinical studies, 
3 (8%) had a partial response (PR), 17 had stable disease 
(43%) including 8 (20%) who had SD > 6 months, and 
20 patients had progressive disease (PD) with a SD> 
6 months/PR rate of 27.5% (Figure 1).  The highest 
rates of prolonged SD > 6 months/PR were observed 
in patients treated with protocols that included hepatic 
arterial infusion (HAI) of oxaliplatin or paclitaxel (7 of 17 
patients treated on HAI regimens, 41%) or antiangiogenic 
agents (9 of 24 patients, 38%) with 6 of those patients 
receiving treatment that included HAI of oxaliplatin 
combined with systemic bevacizumab (Figure 2; Table 
3). A prolonged SD of 10.8 months was observed in a 
patient with metastatic GC with HER-2/neu amplification 
who was treated on phase I protocols, first combining 
the anti-HER-2/neu antibody trastuzumab and the HER-
2/neu tyrosine kinase inhibitor lapatinib, and then with 
trastuzumab and erlotinib. Prolonged SD lasting 9 months 
was also seen in one patient treated on a first-in-human 
trial using a novel MEK inhibitor. 
Survival and toxicities
For the 40 patients treated on phase I trials, the time 
from diagnosis of advanced (metastatic) disease to primary 
evaluation in the Phase I Clinical Center for Targeted 
Therapy was 13.1 months.  The median time from the 
initial phase I consultation to day 1 of a trial was 16 days. 
The overall median survival from day 1 on a phase I trial 
was 4.2 months (95% CI 3.8 – 8.6 months).  Median PFS 
for 40 treated patients was 2.0 months (95% CI 1.8, 3.4) on 
phase I clinical trials. Among these 40 patients, the median 
PFS on their first-line and second-line prior therapies with 
FDA-approved agents given in the advanced setting was 
3.0 months (95% CI 2.4, 5.0) and 3.0 months (95% CI 
2.3, 4.6), respectively.  Median PFS on their last FDA-
approved treatment before phase I referral was 3.0 months 
(95% CI 2.4, 3.9). In comparison, the median PFS on 
phase I therapy did not differ significantly from that on 
their first-line or second-line FDA-approved agents given 
for advanced disease or their last treatment prior to phase 
I referral (P=0.95, 0.98, 0.76, respectively) (Figure 3A). 
Data were also analyzed from the 32 patients who were 
not enrolled on phase I trials and the PFS of their first-, 
second-line, and last treatment with FDA-approved agents 
prior to phase I referral (3.1, 2.4, 3.0 months, respectively) 
also did not differ significantly from the PFS of the phase 
I-treated patients.
Figure 3: (A) PFS of patients treated on phase I trials 
compared to their first-line, second-line and last systemic 
antitumor therapy given in the advanced setting prior to 
phase I referral. (B) Median overall survival after starting a 
phase I trial. Dotted lines represent 95% confidence intervals for 
the estimated survival probabilities.
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Overall survival from enrollment on a phase I trial 
to date of death is shown in Figure 3B.  Among the 40 
treated patients, 38 (95%) had died at the time of analysis. 
The 90-day mortality was 38% with 25 patients alive at 
3 months after beginning phase I therapy; the 6-month 
mortality was 63% with 15 patients alive at 6 months 
after beginning therapy on phase I trials.  Importantly, 
there was no treatment-related mortality.  Two patients 
treated on different combination regimens that included an 
angiogenesis inhibitor experienced grade 3 gastrointestinal 
bleeding, prompting a change of regimen, with overall 
progression-free period of 10.8 and 16.8 months, 
respectively, on their subsequent phase I trials.  The only 
other grade 3 toxicity that prompted removal from study 
was the development of an arteriovenous fistula in one 
patient due to the placement of the hepatic arterial infusion 
catheter.
Prognostic Factors for Survival
We conducted univariate analysis to evaluate the 
effects on survival of variables including age, sex, race/
ethnicity, ECOG performance status, tumor markers 
(carcinoembryonic antigen [CEA], carbohydrate 
antigens [CAs] CA 19-9, CA 125, CA 27.29); history 
of thromboembolism; number of prior therapies; 
presence of liver metastases; number of metastatic 
sites; leukocyte count; hemoglobin level; platelet count; 
and albumin, lactate dehydrogenase (LDH), alkaline 
phosphatase, bilirubin, alanine aminotransferase, aspartate 
aminotransferase, RMH score and serum creatinine levels 
(Table 2). In univariate analysis, factors associated with a 
shorter Phase I PFS were a higher number of metastatic 
sites (1-2 versus >3; hazard ratio [HR] 3.2, P=0.070), 
elevated serum ALT (> 56 IU/L; HR 5.3, P=0.007), 
elevated serum creatinine (>1.6 mg/dL; P=0.022), and 
high CA19-9 (>35 U/mL; HR 4.8, P=0.010). 
Molecular analysis
Testing for mutations in KRAS, NRAS, BRAF, cKIT, 
EGFR, PIK3CA, TP53, as well as immunohistochemistry 
for PTEN loss and HER-2/neu FISH amplification 
was completed on patients with adequate available 
tissue in the MD Anderson CLIA-certified laboratory. 
DNA was extracted from micro-dissected paraffin-
embedded tumor and analyzed by a PCR-based DNA 
sequencing method to examine codons 12, 13 and 61 of 
Table 3: Characteristics of patients with clinical benefit rate (PR + SD > 6months).
Pt Age/Gender Diagnosis Phase I Regimen(s) Best response
PFS on 
Phase I trial 
(months)
1 57/F Intrahepatic CC HAI Oxaliplatin + IV Bevacizumab + IV 5FU
PR on Phase 
I, NED post 
resection**
16.7
22 55/M Intrahepatic CC HAI Oxaliplatin + IV 5FU + IV Bevacizumab + IV Cetuximab PR 9+
34 47/F Intrahepatic CC HAI Nab-Paclitaxel + IV Gemcitabine + IV Bevacizumab PR 7.1+
8 55/F Intrahepatic CC HAI Oxaliplatin + IV Bevacizumab + IV 5FU SD 6.4
37 69/F Intrahepatic CC HAI Oxaliplatin + IV Bevacizumab + IV 5FU SD 7.2
26 71/F Extrahepatic CC HAI Nab-Paclitaxel SD 7.4
36 61/F Gallbladder carcinoma
Bevacizumab + Trastuzumab 
+ Lapatinib; Trastuzumab + Erlotinib SD 10.4
25 47/M Intrahepatic CC Bevacizumab + Sorafenib SD 10.9
39 67/M Intrahepatic CC HAI Oxaliplatin + IV Bevacizumab + IV 5FU SD 11.3
38 60/F Intrahepatic CC Bevacizumab + Sorafenib; Sirolimus + Cetuximab SD 14.3
15 53/M Intrahepatic CC Novel MEK inhibitor SD 8.9
5-FU fluorouracil; CC cholangiocarcinoma; CR complete response; HAI hepatic arterial infusion; PR partial 
response; SD stable disease
** This patient went on to receive neoadjuvant bevacizumab + proton therapy, followed by an extended 
hepatectomy, ultimately showing no evidence of disease (NED). 
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the KRAS proto-oncogene. Of 11 tested patients, a KRAS 
mutation was detected in the tumor of two patients with 
cholangiocarcinoma, one in codon 12 and another in 
codon 13.[15] A third patient’s gallbladder carcinoma 
demonstrated FISH amplification of HER-2/neu (HER-2/
neu: CEP17 signal ratio: 6.49). This patient maintained 
SD for 27 months with a HER-2/neu targeting agent prior 
to progression; then, phase I therapy including HER-2/
neu targeting agents resulted in SD for an additional 10.8 
months.
DISCUSSION
Treatment options for patients with advanced 
unresectable GC and CC are limited given the poor 
outcomes of even frontline therapies with FDA-approved 
agents.  Complete surgical resection remains the only 
curative modality of therapy, offering benefit only for 
patients with localized disease. The NCCN guidelines for 
relapsed GC and CC highlight the limited clinical trial data 
that can be used to define a standard regimen or definitive 
benefit with an emphasis on clinical trial participation.[3, 
16] 
Approximately 44% of patients with CC and GC 
referred for phase I trials were ineligible, mainly because 
of poor performance status (ECOG PS 3 or greater). 
Our analysis shows 28% of our patients achieved SD 
> 6months/PR mainly with locoregional therapy with 
hepatic arterial infusion and angiogenesis inhibitors, 
suggesting that these modalities merit further investigation 
in similar patients. Additionally, the fact that SD > 
6months was seen with targeted therapies including a 
MEK inhibitor (SD 9 months) and an HER-2/neu targeting 
agent (SD 11 months) may be of investigational interest. 
Indeed, Bendell and colleagues also demonstrated a PR 
in cholangiocarcinoma treated with a MEK 1/2 inhibitor.
[17] Although KRAS mutations may sensitize a tumor to 
MEK inhibitors,[18] the KRAS status of our patient with 
prolonged stable disease on a novel MEK inhibitor was 
unknown due to lack of tissue available for molecular 
analysis. 
Overall, the pattern of molecular aberrations seen 
in GC and CC is slowly emerging.  Somatic mutations of 
KRAS, most commonly G12D and G13D, and PIK3CA, 
most commonly E545K, along with deletion of p53 have 
been reported in CCs; activating mutations in PIK3CA 
have also been reported in 12.5% of patients with GC, 
highlighting the therapeutic targeting potential of the 
RAS/RAF/MEK/ERK pathway and PI3K/AKT/MTOR 
pathway.[19, 20] It is conceivable that the responses 
to MEK inhibitors seen in CC are due to the frequency 
of KRAS mutations among these patients (13%).[20] 
Most recently, tissue from 9 of 40 patients (23%) with 
intrahepatic CC was shown to harbor mutations in the gene 
encoding isocitrate dehydrogenase 1 (IDH1).[21]  The 
clinical significance of this is not known, but one proposed 
mechanism demonstrates that a heterozygous IDH1 
mutation leads to elevated levels of hypoxia-inducible 
factor subunit HIF-1alpha, thereby promoting tumor 
development and suggesting that IDH1 may be a tumor 
suppressor.  We have recently shown that better response 
rates, time to treatment failure, and overall survival are 
associated with matching therapy to actionable mutations, 
highlighting the importance of further assessment of this 
strategy in these populations.[22]  
Our analysis demonstrates that the PFS of phase 
I therapy in our program is comparable to that of the 
first-line, second-line and last prior treatment options 
with FDA-approved agents for advanced disease. There 
are several limitations to our analysis. First, a selection 
bias exists within our patient population given that 
the patients presented with widely metastatic disease 
and the PFS on frontline therapies in this population, 
particularly following treatment with the gemcitabine/
cisplatin combination, was shorter than that reported in 
the pivotal phase III trial.[14] Such findings may suggest 
a more aggressive tumor behavior that has yet to be 
characterized among our patients. Second, a substantial 
number of patients (32 of 72 referred patients, 44%) were 
not enrolled on a phase I trial. This was due, for the most 
part, to clinical deterioration, although the first-, second-, 
and last line PFS among these untreated patients did 
not differ from that of the 40 patients treated on a phase 
I trial. Thirdly, we were unable to conduct an effective 
multivariate analysis given the small sample size. Finally, 
mutational analysis was only performed in a small subset 
of patients due to the lack of tissue availability for testing. 
Additionally, data on quality of life as an endpoint was not 
Table 4: Molecular analyses of the 40 
treated patients treated on Phase I trials.
Molecular 
mutation or 
aberration
Number 
of patients 
tested
Number of 
patients with 
a mutation or 
aberration
KRAS 11 2
NRAS 7 0
BRAF 10 0
CKIT 3 0
EGFR 10 0
PI3K 9 0
GNAQ 1 0
PTEN Loss 3 0
ER IHC 6 0
PR IHC 6 0
HER-2/neu FISH 8 1
Abbreviations: IHC immunohistochemistry; FISH 
fluorescence in situ hybridization
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collected and, given the poor prognosis of these patients, 
an emphasis on quality of life measurements becomes 
critical. Future clinical trials should include quality of life 
as an important end point.
Predictors of shorter phase I PFS in univariate 
analysis were a higher number of metastatic site (>3), 
elevated serum ALT (>56 IU/L), elevated serum creatinine 
(>1.6 mg/dL), and high CA19-9 (>35 U/mL). Overall, the 
short PFS reflects the rather dismal outcomes of these 
advanced GC and CC patients and emphasizes the need 
for new approaches.  Since 28% of our patients who were 
able to enroll of a trial achieved SD > 6 months/PR mainly 
on our trials with locoregional therapy, anti-angiogenic 
agents, MEK and HER-2/neu inhibitors, these strategies 
may merit further exploration.
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